Zoetis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Zoetis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ZTS

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. It operates through the United States and International geographical segments. 

CEO
Kristin C. Peck
CEOKristin C. Peck
Employees
14,500
Employees14,500
Headquarters
Parsippany, New Jersey
HeadquartersParsippany, New Jersey
Founded
1952
Founded1952
Employees
14,500
Employees14,500

ZTS Key Statistics

Market cap
32.04B
Market cap32.04B
Price-Earnings ratio
12.71
Price-Earnings ratio12.71
Dividend yield
2.70%
Dividend yield2.70%
Average volume
4.90M
Average volume4.90M
High today
$78.75
High today$78.75
Low today
$76.62
Low today$76.62
Open price
$76.62
Open price$76.62
Volume
4.85M
Volume4.85M
52 Week high
$156.49
52 Week high$156.49
52 Week low
$71.00
52 Week low$71.00

Stock Snapshot

Zoetis(ZTS) stock is priced at $77.70, giving the company a market capitalization of 32.04B. It carries a P/E multiple of 12.71 and pays a dividend yield of 2.70%.

On 2026-08-26, Zoetis(ZTS) stock traded between a low of $76.62 and a high of $78.75. Shares are currently priced at $77.70, which is +1.4% above the low and -1.3% below the high.

The Zoetis(ZTS)'s current trading volume is 4.85M, compared to an average daily volume of 4.9M.

In the last year, Zoetis(ZTS) shares hit a 52-week high of $156.49 and a 52-week low of $71.00.

In the last year, Zoetis(ZTS) shares hit a 52-week high of $156.49 and a 52-week low of $71.00.

ZTS News

Simply Wall St 1d
The Bull Case For Zoetis Could Change Following FDA Emergency Use Authorization For Simparica Trio

On 13 August 2026, Zoetis Inc. announced that its Simparica Trio chewable received U.S. FDA Emergency Use Authorization to treat life-threatening New World scre...

The Bull Case For Zoetis Could Change Following FDA Emergency Use Authorization For Simparica Trio
TipRanks 2d
Zoetis price target lowered to $94 from $104 at TD Cowen

TD Cowen analyst Steve Scala lowered the firm’s price target on Zoetis (ZTS) to $94 from $104 and keeps a Buy rating on the shares. The firm reduced their near-...

Analyst ratings

55%

of 20 ratings
Buy
45%
Hold
55%
Sell
0%

People also own

Based on the portfolios of people who own ZTS. This list is generated using Robinhood data, and it’s not a recommendation.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.